Patents by Inventor Richard Hendrik Blaauw

Richard Hendrik Blaauw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemiluminescence-based haemostasis assay
    Patent number: 10465230
    Abstract: The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: November 5, 2019
    Assignee: STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Waander Laurens Van Heerde, Richard Hendrik Blaauw
  • CHEMILUMINESCENCE-BASED HAEMOSTASIS ASSAY
    Publication number: 20180208963
    Abstract: The present invention relates to a method for in vitro determining generation of a haemostasis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.
    Type: Application
    Filed: December 18, 2017
    Publication date: July 26, 2018
    Inventors: Waander Laurens Van Heerde, Richard Hendrik Blaauw
  • Chemiluminescence-based haemostasis assay
    Patent number: 9856510
    Abstract: The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: January 2, 2018
    Assignees: Stichting Katholieke Universiteit, Chiralix B.V.
    Inventors: Waander Laurens van Heerde, Richard Hendrik Blaauw
  • Chromanyl derivatives for treating mitochondrial disease
    Patent number: 9388156
    Abstract: The invention relates to novel compounds that are useful for modulating mitochondrial morphology and/or expression of OXPHOS enzymes and/or cellular ROS. The compounds are derivatives of TroloxrM wherein the carboxylic acid moiety is replaced by an amide moiety and wherein the nitrogen atom of the amide moiety is connected via a linker to a cationic nitrogen atom. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing mitochondrial disorders, conditions associated with mitochondrial dysfunction, including adverse drug effects, and/or neoplastic diseases. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: July 12, 2016
    Assignee: Khondiron IP B.V.
    Inventors: Richard Hendrik Blaauw, Ruben Gerardus George Leenders, Geert Jan Sterk, Pedro Harold Han Hermkens
  • CHROMANYL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASE
    Publication number: 20150166501
    Abstract: The invention relates to novel compounds that are useful for modulating mitochondrial morphology and/or expression of OXPHOS enzymes and/or cellular ROS. The compounds are derivatives of TroloxrM wherein the carboxylic acid moiety is replaced by an amide moiety and wherein the nitrogen atom of the amide moiety is connected via a linker to a cationic nitrogen atom. The compounds of the invention are formulated into pharmaceutical or cosmetic compositions. The invention further relates to methods wherein the compounds of the invention are used for treating or preventing mitochondrial disorders, conditions associated with mitochondrial dysfunction, including adverse drug effects, and/or neoplastic diseases. The invention also relates to cosmetic methods for treating or delaying further aging of the skin and veterinary applications.
    Type: Application
    Filed: July 12, 2013
    Publication date: June 18, 2015
    Applicant: Khondrion IP B.V.
    Inventors: Richard Hendrik Blaauw, Ruben Gerardus George Leenders, Geert Jan Sterk, Pedro Harold Han Hermkens
  • CHEMILUMINESCENCE-BASED HAEMOSTASIS ASSAY
    Publication number: 20130337480
    Abstract: The present invention relates to a method for in vitro determining generation of a haemostatis factor such as thrombin and/or plasmin in a test sample using a chemiluminescent substrate specific for said blood clotting factor. Upon cleavage of the substrate, a luminescent signal is generated via aminoluceferin with the aid of a luciferase. The invention also relates to a kit for in vitro determining generation of a haemostasis factor in a test sample, and to novel chemiluminescent substrates for the determination of thrombin and plasmin.
    Type: Application
    Filed: December 14, 2011
    Publication date: December 19, 2013
    Applicants: CHIRALIX B.V., STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Waander Laurens Van Heerde, Richard Hendrik Blaauw
  • Peptidylarginine deiminase (PAD) inhibitors
    Patent number: 8404647
    Abstract: The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: March 26, 2013
    Assignees: Chiralix B.V., Modiquest B.V., Academisch Ziekenhuis Leiden H.O.D.N. Lumc
    Inventors: Richard Hendrik Blaauw, Gerardus Jozef Maria Pruijn, Jozef Maria Hendrik Raats, Floris Petrus Johannes Theodorus Rutjes, Jan Wouter Drijfhout
  • Peptidylarginine Deiminase (PAD) Inhibitors
    Publication number: 20110142868
    Abstract: The invention relates to PAD inhibitors that are suitable to be used as a medicament against an autoimmune disease such as RA.
    Type: Application
    Filed: December 10, 2010
    Publication date: June 16, 2011
    Applicants: Chiralix B.V., ModiQuest V.V., Academisch Ziekenhuis Leiden h.o.d.n. LUMC
    Inventors: Richard Hendrik Blaauw, Gerardus Jozef Maria Pruijn, Jozef Maria Hendrik Raats, Floris Petrus Johannes Theodorus Rutjes, Jan Wouter Drijfhout